Egyptian Journal of Basic and Clinical Pharmacology
Vol. 4 (2014), Issue 1-2, pp. 73-87
doi:10.11131/2014/101348
Possible Effect of Mosapride on Gastric Mucosa and Indomethacin Induced Gastric Ulcer in Male Albino Rats
Abstract
Background: Mosapride, a gastroprokinetic agent that acts as a selective 5HT4 agonist, is used for the treatment of gastritis, gastro-oesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. Non-steroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling. Peptic ulcer is a major side effect of NSAIDs. In this study we tested the effect of oral administration of mosapride 0.25, 0.5, 0.75, 1.25, 2.5 and 5mg/kg on gastric mucosa and on NSAIDs induced gastric ulcers in rats. Methods: Acute gastric ulcers were induced in rats by the oral administration of indomethacin. Results: Mosapride had no effect on gastric mucosa but increased the prostaglandin E2 (PGE2) level. Pretreatment with mosapride at 0.25 and 0.5 mg/kg prevented the mucosal damage induced by indomethacin. The higher doses, from 0.75 up to 5mg/kg, had no effect on indomethacin-induced gastric ulcer. Conclusion: Mosapride had no effect on gastric mucosa but increased PGE2 and demonstrated anti-ulcer effect in small doses only. This effect could be partially mediated through increased prostaglandin E2.
Egyptian Journal of Basic and Clinical Pharmacology
Vol. 4 (2014), Issue 1-2, pp. 73-87
doi:10.11131/2014/101348
Possible Effect of Mosapride on Gastric Mucosa and Indomethacin Induced Gastric Ulcer in Male Albino Rats
Abstract
Background: Mosapride, a gastroprokinetic agent that acts as a selective 5HT4 agonist, is used for the treatment of gastritis, gastro-oesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. Non-steroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling. Peptic ulcer is a major side effect of NSAIDs. In this study we tested the effect of oral administration of mosapride 0.25, 0.5, 0.75, 1.25, 2.5 and 5mg/kg on gastric mucosa and on NSAIDs induced gastric ulcers in rats. Methods: Acute gastric ulcers were induced in rats by the oral administration of indomethacin. Results: Mosapride had no effect on gastric mucosa but increased the prostaglandin E2 (PGE2) level. Pretreatment with mosapride at 0.25 and 0.5 mg/kg prevented the mucosal damage induced by indomethacin. The higher doses, from 0.75 up to 5mg/kg, had no effect on indomethacin-induced gastric ulcer. Conclusion: Mosapride had no effect on gastric mucosa but increased PGE2 and demonstrated anti-ulcer effect in small doses only. This effect could be partially mediated through increased prostaglandin E2.
Egyptian Journal of Basic and Clinical Pharmacology
Vol. 4 (2014), Issue 1-2, pp. 73-87
doi:10.11131/2014/101348
Possible Effect of Mosapride on Gastric Mucosa and Indomethacin Induced Gastric Ulcer in Male Albino Rats
How to Cite this Article
Sohair S. El Menshawy, Gehane A. El-Gindy, Ahmed A. Abd El-Sameea, Amira M. Abd Elhamid, Amira A., and Laila R., “Possible Effect of Mosapride on Gastric Mucosa and Indomethacin Induced Gastric Ulcer in Male Albino Rats,” Egyptian Journal of Basic and Clinical Pharmacology, Vol. 4, Issue 1-2, pp. 73-87, 2014. doi:10.11131/2014/101348